中国医院用药评价与分析2025，Vol.25Issue(2)：230-234,239,6.DOI:10.14009/j.issn.1672-2124.2025.02.023
维得利珠单抗致药物性肝损伤的文献病例分析
Literature Case Analysis of Drug-Induced Liver Injury Induced by Vedolizumab
摘要
Abstract
OBJECTIVE:To probe into the clinical characteristics of drug-induced liver injury(DILI)induced by vedolizumab(VDZ),so as to provide reference for rational drug use in clinic.METHODS:PubMed,Embase,CNKI,VIP,and Wanfang Data were retrieved to collect case reports related to DILI induced by VDZ up to Mar.2024.The case reports were classified and analyzed.RESULTS:A total of 9 patients in 6 articles were enrolled,including 6 males(66.67％)and 3 females(33.33％),aged from 23 to 82 years,with an average age of(38.11±17.72)years.DILI occurred from 14 to 275 d after the first treatment of VDZ,and 5 cases(55.56％)occurred after the third medication.The clinical manifestations of DILI were insidious,with only 2 patients experienced symptoms of fatigue and skin yellowing at the initial diagnosis.Abnormal liver function tests mainly manifested as elevated levels of aspartate transaminase,alanine transaminase,bilirubin,and alkaline phosphatase.The main types of liver injury in patients was cholestasis(6 case,66.67％).The prognosis was good,with 8 patients(88.89％)experiencing normal liver function within 6 months after drug withdrawal or intervention.CONCLUSIONS:In the course of clinical application of VDZ,it should be noted that it may induce DILI,especially cholestatic DILI.By understanding the history of drug treatment,determining the time correlation,and based on patients'clinical symptoms,liver function testing,liver examination,and histopathological examination,the clear diagnosis can be made.If necessary,stop using suspicious drugs and adjust treatment plans in a timely manner to ensure medication safety.关键词
维得利珠单抗/不良反应/药物性肝损伤/文献病例分析Key words
Vedolizumab/Adverse drug reactions/Drug-induced liver injury/Literature case analysis分类
医药卫生引用本文复制引用
郁件康,郁文刘,陈世祺,李芸..维得利珠单抗致药物性肝损伤的文献病例分析[J].中国医院用药评价与分析,2025,25(2):230-234,239,6.基金项目
国家临床重点专科(临床药学)建设项目(卫生部部属(管)医疗机构临床学科重点项目建设专项资金)(No.国卫办医函〔2018〕292 号) （临床药学）
江苏省医学重点学科(No.ZDXK202247) （No.ZDXK202247）
